

The discovery of AZD-2098 and AZD-1678, two potent and bioavailable CCR4 receptor antagonists.

Nicholas D. Kindon, Glen Andrews, Andrew Baxter, David Cheshire, Paul Hemsley, Timothy Johnson, Yu-Zhen Liu, Dermot McGinnity, Mark McHale, Antonio Mete, James Reuberson, Bryan Roberts, John Steele, Barry Teobald, John Unitt, Deborah Vaughan, Iain Walters, and Michael John Stocks

ACS Med. Chem. Lett., **Just Accepted Manuscript** • DOI: 10.1021/acsmedchemlett.7b00315 • Publication Date (Web): 01 Sep 2017

Downloaded from <http://pubs.acs.org> on September 2, 2017

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



The discovery of AZD-2098 and AZD-1678, two potent and bioavailable CCR₄ receptor antagonists.

Nicholas Kindon,^{a, b} Glen Andrews,^a Andrew Baxter,^a David Cheshire,^a Paul Hemsley,^{a, c} Timothy Johnson,^a Yu-Zhen Liu,^a Dermot McGinnity,^{a, d} Mark McHale,^a Antonio Mete,^a James Reuberson,^a Bryan Roberts,^a John Steele,^{a, e} Barry Teobald,^a John Unitt,^a Deborah Vaughan,^a Iain Walters,^a and Michael J. Stocks*^{a, b}

^a AstraZeneca R&D Charnwood, Bakewell Road, Loughborough, LE11 5RH, UK.

^b Current address School of Pharmacy, Centre for Biomolecular Sciences, The University of Nottingham, University Park, Nottingham, NG7 2RD, UK.

^c Current address Discovery Sciences, Innovative Medicines & Early Development, AstraZeneca, Darwin Building, Cambridge Science Park, Cambridge, CB4 0FZ UK.

^d Current address IMED Oncology, Innovative Medicines & Early Development, AstraZeneca, Chesterford Research Park, Cambridge, CB10 1XL, UK

^e Respiratory, Inflammation and Autoimmunity, Innovative Medicines and Early Development, AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83 Mölndal, Sweden

KEYWORDS Chemokine receptor 4; MDC; TARC; CCR₄; Antagonist

ABSTRACT: *N*-(5-Bromo-3-methoxypyrazin-2-yl)-5-chlorothiophene-2-sulfonamide **1** was identified as a hit in a CCR₄ receptor antagonist high throughput screen (HTS) of a sub-set of the AstraZeneca compound bank. As a hit with a lead-like profile, it was an excellent starting point for a CCR₄ receptor antagonist program and enabled the rapid progression through the Lead Identification and Lead Optimization phases resulting in the discovery of two bioavailable CCR₄ receptor antagonist candidate drugs.

The chemokine receptor family was originally identified in the 1990s and has since grown in number, complexity and range of biological functions. Originally thought to be simple cell chemo attractants, chemokines have since been shown to exhibit a broader range of functions covering involvement in HIV-1 infection to hematopoiesis and control of cell growth.^{1,2}

CCR₄ is a G protein-coupled receptor (GPCR) and is activated by the CC chemokines, CCL22 (MDC: macrophage-derived chemokine) and CCL17 (TARC: T-cell and activation-related chemokine),³ leading to cell activation and chemotaxis; it is expressed mainly by Th2 lymphocytes.^{4,5} In keeping with a role for CCR₄ in the orchestrated movement of Th2 cells into the allergic lung, both CCL17 and CCL22 have been shown to be elevated in the human lung following allergen challenge.⁶ This potential role of CCR₄ in driving human allergic lung disease led to many pharmaceutical companies attempting to identify CCR₄ receptor antagonists for the treatment of allergic rhinitis and asthma,^{7–14,15} but as yet no drug has been discovered (Figure 1).^{16,17}





Figure 1: Structures of a selection of recently published CCR₄ receptor antagonists.

In this communication we are disclosing our studies on the optimization of *N*-(5-bromo-3-methoxypyrazin-2-yl)-5-chlorothiophene-2-sulfonamide **1** to afford two clinical candidates AZD-2098 (**47**) and AZD-1678 (**49**). High throughput screening of the AstraZeneca Mixed Chemokine Receptor Antagonist Compound library (~29,000 compounds) using a *h*CCR₄ Fluorescent Microvolume Assay Technology (FMAT) cell binding assay identified compound **1**^{18,19} as an inhibitor of labeled CCL22 binding to CCR₄ (pIC₅₀ 7.2).²⁰ Subsequently functional antagonism of **1** was shown using an *h*CCR₄ Fluorescence Imaging Plate Reader (FLIPR) intracellular calcium mobilization assay (pIC₅₀ 7.0) and a human primary Th2 cell chemotaxis assay (pIC₅₀ 6.7).

Table 1 Hit profile of pyrazine sulfonamide **1**

Biological Assay / test procedure	Compound 1
hCCR4 Binding (pIC ₅₀)	7.2 ± 0.2
hPPB (%)	>99.9
Calc. WBP (pIC ₅₀)*	<4.2
logD	1.1
Solubility (mg/mL)	0.34
human hepatocytes (μL/mL/10 ⁶ cells)	<0.2
rat / mouse in vivo PK	
Cl (mL/min/kg)	0.1 / 0.1
V _{ss} (L/kg)	0.1 / 0.1
T _{1/2} (h)	16 / 10
Bioavailability (%)	45 / 86
Rat / mouse CCR4 binding (pIC ₅₀)	8.3 / 8.3
Rat / mouse PPB (%)	99.85 / 96.7

*Calculated from the hCCR4 binding and %age PPB

Compound **1** exhibited a good lead-like profile²¹ and was shown to be selective for the CCR4 receptor, through screening against an internal panel of chemokine receptors (e.g. CXCR1 & CXCR2, CCR1, CCR2b, CCR5, CCR7 & CCR8; inactive at 10 μM). When screened against a large panel of receptors and enzymes (~120 screens at MDS-Pharma), weak or no activity was observed and therefore **1** was chosen as a starting point for the CCR4 antagonist program. Compound **1** had good solubility (0.34 mg/mL), rat bioavailability (F = 45%) and half-life (T_{1/2} ~16 h) when dosed in rat and a similar profile when dose *in vivo* in mouse. This long half-life was accounted for by a very low clearance (0.1 mL/min/kg), which counteracts the small volume of distribution (V_{ss} 0.1 L/kg).

Compound **1** had very good cross-over with rat and mouse CCR4 receptors (both pIC₅₀ 8.3). Subsequently, this species cross-over was shown to be a general feature of the sulfonamide series (see Table 5), with the CCR4 receptor from all three species displaying very similar structural activity relationships (SAR). When corrected for plasma protein binding, the predicted rat whole blood potency of **1** was pIC₅₀ 5.5 (rat ppb 99.85%) and for mouse 6.8 (mouse ppb 96.7%), giving **1** a suitable profile for use as a target validation tool for *in vivo* hypothesis testing.


However, the calculated human whole blood potency (WBP) was very poor with predicted activity (pIC₅₀) < 4.2 (calculated from hCCR4 pIC₅₀ 7.2 and hPPB >99.9%).

With a candidate drug requiring a WBP pIC₅₀ ~ 6.0, the key issue was to increase WBP by a combination of increasing CCR4 receptor affinity and lowering plasma protein binding,²² whilst maintaining all the other good features inherent in **1**. The high plasma protein binding was attributed to the acidic sulfonamide-NH (measured pKa

4.1) and the lipophilic nature of the molecule (measured logP 4.4).

The structure activity relationship (SAR) generated with respect to modification of the 5-chlorothiophene group is shown in Table 2. Removal of the 5-chloro substituent **2** gave over a 10-fold drop in affinity, as did the isomeric unsubstituted thiophene **3**. Addition of a chlorine to the 4-position of the thienyl group also gave a reduction in affinity (compare **4** with **1**) whilst a large substituent (bromine or phenyl) in the 3-position was tolerated (compare **5** and **6** with **1** and **2** respectively). The phenyl analogue **7** was similar to the two unsubstituted thiophenes in potency and introducing chlorine into the 2-, 3- or 4-positions of the phenyl sulfonamide ring (**8**, **9** and **10**) gave an increase in binding relative to **7**. The 6-substituted dichlorophenyl sulfonamides (**11-17**) had a potency range of almost 3 log units, with the 3,5-dichlorophenylsulfonamide analogue **14** having only weak activity (pIC₅₀ 5.3) and the 2,3-dichlorophenylsulfonamide **16** being optimal (pIC₅₀ 8.0), almost a log unit more potent than **1**. Similar affinity was achieved with 3, 4-dichloro-2-thienyl (compare **18** and **17**). A number of other di-substituted phenyl sulfonamides were screened, however no improvement in binding was seen (**19-24** compare with **17**). Introduction of a nitrogen into the aromatic ring lead to dramatic reduction in potency (**25**) as did replacement of the aromatic ring with an alkyl group as illustrated with **26**.

Whilst an increase in affinity was achieved with compounds **16** and **17**, changing the 5-chlorothiophene group for 2, 3-dichlorophenyl did not significantly change the lipophilicity. Consequently, the hPPB figures for these two compounds was also high (>99.9%).

Table 2 Exploration of the 5-position of the pyrazine ring


Example	R	X	CCR4 pIC ₅₀ ^a
1	5-Chloro-2-thienyl	Br	7.2 ± 0.2
2	2-Thienyl	Br	6.2 ± 0.2
3	3-Thienyl	Br	5.9 ± 0.1
4	4,5-Dichloro-2-thienyl	Br	6.0 ± 0.1
5	3-Bromo-5-chloro-2-thienyl	Br	7.4 ± 0.2
6	3-Phenyl-2-thienyl	Br	6.0 ± 0.1
7	Phenyl	Br	6.1 ± 0.1
8	2-Chlorophenyl	Br	6.8 ± 0.2
9	3-Chlorophenyl	Br	7.0 ± 0.2
10	4-Chlorophenyl	Br	6.9 ± 0.2
11	2,6-Dichlorophenyl	Br	6.2 ± 0.2
12	2,5-Dichlorophenyl	Br	5.5 ± 0.1
13	2,4-Dichlorophenyl	Br	6.9 ± 0.2
14	3,5-Dichlorophenyl	Br	5.3 ± 0.1
15	3,4-Dichlorophenyl	Br	6.7 ± 0.2

16	2,3-Dichlorophenyl	Br	8.0 ± 0.2
17	2,3-Dichlorophenyl	Cl	7.9 ± 0.2
18	3,4-Dichloro-2-thienyl	Cl	8.1 ± 0.2
19	2-Chloro-3-fluorophenyl	Cl	7.8 ± 0.2
20	3-Chloro-2-fluorophenyl	Cl	7.1 ± 0.2
21	3-Chloro-2-methylphenyl	Cl	7.7 ± 0.2
22	2-Chloro-3-(trifluoromethyl)phenyl	Cl	7.2 ± 0.1
23	3-Chloro-2-cyanophenyl	Cl	7.2 ± 0.2
24	3-Chloro-2-methylthiophenyl	Cl	7.1 ± 0.2
25	2,3-Dichloro-4-pyridyl	Cl	5.0 ± 0.1
26	Butyl	Cl	5.5 ± 0.2

^a Potency is given as pIC₅₀ values with n = ≥ 2 replicates.

The exploration of the 3-position is shown in Table 3. Initially the atom linking the 3-substituent to the pyrazine ring was investigated. Changing methoxy for me-

Table 3 Exploration of the 3-position of the pyrazine ring.




Example	R ₂	R ₃	R ₄	CCR4 receptor antagonism (pIC ₅₀) ^a
27	OEt	Br	5-Chloro-2-thienyl	6.7 ± 0.2
28	SMe	Br	5-Chloro-2-thienyl	5.5 ± 0.2
29	NHMe	Br	5-Chloro-2-thienyl	<5.0*
30	Et	Br	5-Chloro-2-thienyl	5.3 ± 0.2
31	OBu	Cl	2,3-Dichlorophenyl	6.8 ± 0.1
32	OCH ₂ ^t Bu	Cl	2,3-Dichlorophenyl	5.1 ± 0.2
33	OCH ₂ CHCH ₂	Cl	2,3-Dichlorophenyl	7.8 ± 0.1
34	OCH ₂ CCH	Cl	2,3-Dichlorophenyl	8.6 ± 0.2
35		Cl	2,3-Dichlorophenyl	9.2 ± 0.3
36		Cl	2,3-Dichlorophenyl	8.4 ± 0.2
37		Cl	2,3-Dichlorophenyl	9.5 ± 0.2
38		Cl	2,3-Dichlorophenyl	7.9 ± 0.3

^a Potency is given as pIC₅₀ values with n = ≥ 2 replicates. *44% inhibition at 10 μM

In contrast to the 3-position, the exploration of the 5- and 6-positions on the pyrazine ring allowed for the discovery of compounds with increased activity combined with lower lipophilicity relative to **17** (Table 4).

Table 4 Exploration of the 5- and 6- position of the pyrazine ring.




Example	X	R ₅	R ₆	CCR4 receptor antagonism (pIC ₅₀) ^a	LogP	hPPB (%)	Calc. WBP (pIC ₅₀)
17	CH=CH	Cl	H	7.9 ± 0.2	4.1	>99.9	-

39	CH=CH	H	Cl	8.1 ± 0.3	4.5	>99.9	-
40	CH=CH	OEt	H	7.9 ± 0.2	4.1	>99.9	-
41	CH=CH	SO ₂ Me	H	5.3 ± 0.2	-	-	-
42	CH=CH	Me	H	7.4 ± 0.2	3.0	99.65	4.9
43	CH=CH	H	Me	7.3 ± 0.3	-	>99.8	-
44	CH=CH	CH ₂ OH	H	7.6 ± 0.2	2.1	96.2	6.2
45	CH=CH	CH ₂ OH	Cl	8.4 ± 0.2	3.2	99.6	6.0
46	CH=CH	CH ₂ OH	Me	7.4 ± 0.1	2.4	98.7	5.5
47	CH=CH	H	H	7.8 ± 0.05	2.5	98.9	5.8
48	S	H	H	7.7 ± 0.2	2.8	97.5	6.1
49	CH=CH	F	H	8.6 ± 0.1	3.1	99.4	6.4
50	CH=CH	H	F	8.4 ± 0.2	3.3	>99.8	-
51	CH=CH	F	F	9.0 ± 0.3	-	>99.8	-

^a Potency is given as pIC₅₀ values with n = ≥ 2 replicates.

A wide variety of substituents were tolerated in the 5- and 6-positions and it was discovered that the percentage plasma protein binding was reduced by lowering the lipophilicity of the compounds, affording plasma protein binding below 99% for compounds of modest lipophilicity (logP < 3.0). For **44**, **45**, **47**, **48** and **49**, the calculated WBP (pIC₅₀) of 5.8-6.4 was achieved. These met the candidate drug target profile set of WBP pIC₅₀ ~ 6.0. Of these four compounds, **47** and **49** had the best overall profile for progression (Table 5). Compounds **47** and **49** demonstrated good selectivity for the CCR₄ receptor when screened in-house against a range of other chemokine receptors (CXCR₁ & CXCR₂, CCR₁, CCR_{2b}, CCR₅, CCR₇ & CCR₈; all inactive at 10 μM) and little or no activity when screened against a large panel of receptors and enzymes (~120 screens at MDS-Pharma). A pharmacokinetic profile commensurate with once-daily oral administration enabled both compounds to progress as candidate drugs.²³

Table 5 Compound profiles of 47 and 49



Screen	47 (R ⁷ = H)	49 (R ⁷ = F)
hCCR ₄ pIC ₅₀	7.8 ± 0.05 (n = 11)	8.6 ± 0.1 (n = 10)
hPPB (%)	98.9	99.4
Calc. WBP (pIC ₅₀)	5.9	6.4
logD	0.35	0.6
Solubility (mg/mL)	1.5	1.3
Human hepatocytes (μL/mL/10 ⁶ cells)	<0.2	<1.0
Species cross over		
Rat CCR ₄ pIC ₅₀	8.0 ± 0.27 (n = 3)	9.0 ± 0.1 (n = 3)
Mouse CCR ₄ pIC ₅₀	8.0 ± 0.04 (n = 3)	9.0 ± 0.1 (n = 3)
Dog CCR ₄ pIC ₅₀	7.6 ± 0.06 (n = 7)	8.5 ± 0.2 (n = 3)
Rat/dog in vivo PK*		
Cl (mL/min/kg)	2.0/1.5	2.3/3.7
V _{ss} (L/kg)	0.2/0.1	0.2/0.2
T _{1/2} (h)	1.7/1.0	2.5/0.5

F (%)	100/100	100/100
dose-to-man prediction (mg/kg) UID	1	0.1

*PK studies conducted using 1% sodium bicarbonate solution at 9.0 μMol/kg (p.o.) or 3.0 μMol/kg (i.v.)

The antagonist potency of **47** and **49** were assessed in a number of cell systems in which a response mediated by the human CCR₄ receptor can be evoked by MDC or TARC and quantified using changes in intracellular calcium concentration or chemotaxis. The cell systems used were a cell line (CHO) transfected with the human CCR₄ receptor and human CD4⁺, CD45RA⁺ Th2 cells in 0.3% HSA. Findings are summarized in Table 6. The reduced potency in the presence of added protein is consistent with the drop-off predicted from plasma protein binding measurements. Both **47** and **49** demonstrated no agonist activity at concentrations up to 10 μM.

Table 6 Potency of 47 and 49 for inhibition of cellular responses mediated by the human CCR₄ receptor

Cell system	Assay readout	47 (pIC ₅₀ mean ± SEM)	49 (pIC ₅₀ mean ± SEM)
Inhibition of CCL22 Ca ²⁺ re-sponse	MDC-induced Ca ²⁺ flux	7.5 ± 0.04 (n=3) (CHO cells expressing hCCR ₄)	8.4 ± 0.1 (n=4) (HEK cells expressing hCCR ₄)
Inhibition of Th2 cell CCL22 driven chemotaxis in 0.3% HSA	MDC-induced chemotaxis	6.3 ± 0.2 (n=3)	6.8 ± 0.2 (n=3)
Inhibition of Th2 cell CCL17 driven chemotaxis in 0.3% HSA	TARC-induced chemotaxis	6.3 ± 0.1 (n=3)	6.5 (n=1)

The anti-inflammatory effects of **47** were investigated in Brown-Norway rats sensitized to ovalbumin. Sensitized rats were dosed orally (bid) with **47** at 0.22, 0.75, 2.2, 3.0, 7.5 and 15 μmol/kg 1 hour prior to antigen challenge and every 12 hours thereafter prior to termination 96 hours


post challenge. Histopathological examination of the lung tissue showed a marked, dose-dependent reduction in a range of histological correlates with reduced alveolitis and leukocyte trafficking in the microvasculature being the most diagnostic features of efficacy. The changes were first visible at a dose of 0.22 $\mu\text{mol/kg}$ and maximal at 7.5 $\mu\text{mol/kg}$. Plasma samples were taken 12 hours after the last dose of compound for measurement of terminal trough concentrations of **47** to demonstrate a strong PKPD correlation (Table 7).

Table 7 Terminal plasma concentrations of **47**

Dose ($\mu\text{mol/kg}$)	Total plasma concentration (μM)	Free plasma concentration/pIC ₅₀
0.22	<LOQ*	-
0.75	<LOQ*	-
2.2	<LOQ*	-
3.0	0.033 \pm 0.018	0.6
7.5	0.14 \pm 0.069	3
15	0.49 \pm 0.18	9

*LOQ was 0.03 μM for the 0.22, 0.75 and 2.2 $\mu\text{mol/kg}$ doses

The synthesis of **47** and **49** is shown (Scheme 1). Dibromination of 2-aminopyrazine followed by selective displacement of the bromine in the 3-position with sodium methoxide gave 2-amino-5-bromo-3-methoxypyrazine. The bromine in the 5-position was then removed by hydrogenation and coupling of the 2, 3-dichlorophenylsulfonyl chloride with 2-amino-3-methoxypyrazine afforded **47**. A highly-selective 5-position nitration of **47** followed by reduction of the nitro group **52** gave an amino-pyrazine **53** that was diazotized in the presence of hydrofluoric acid to give **49**.



REFERENCES

- (1) Pease, J.; Horuk, R. Chemokine Receptor Antagonists. *J. Med. Chem.* **2012**, 55 (22), 9363–9392.
- (2) Charo, I. F.; Ransohoff, R. M. The Many Roles of Chemokines and Chemokine Receptors in Inflammation. *N. Engl. J. Med.* **2006**, 354 (6), 610–621.

Scheme 1. i) Br₂, dichloromethane, 2,6-lutidine (85–95%) ii) NaOMe (3 eq.), MeOH, reflux (90–95%) iii) H₂, Pd/C, ethanol, rt (95%) iv) ArSO₂Cl, KOtBu, 0–25 °C, THF (80–95%) v) HNO₃, AcOH, 70–85 °C (75–82%) vi) H₂, Pd/C, AcOH, 60 °C (75–92%) vii) HBF₄, CH₃CN, 0–5 °C, NaNO₂ (40%) or HF / Pyridine / NaNO₂ (85%). Range of percentage yields across multiple reactions and scale (~100 mg to >50g).

In summary, a new series of potent and bioavailable amino-pyrazine sulfonamide CCR₄ receptor antagonists have been developed from a lead optimization program initiated from a high-throughput screening / synthesis campaign. The initial hit series proved to have reasonable activity but was hindered by having very high human plasma protein binding resulting in a low free fraction of compound. Through chemical modification, both the potency of the series and the free fraction was enhanced to ultimately deliver two clinical candidates. Further studies on these compounds will be reported in due course.

Supporting Information

Representative synthetic procedures and analytical data for **47** and **49**. Description of biological assay (CCR₄ receptor antagonism using FMAT whole cell binding).

The Supporting Information is available free of charge on the ACS Publications website.

AUTHOR INFORMATION

Corresponding Author

* michael.stocks@nottingham.ac.uk

Author Contributions

All authors have given approval to the final version of the manuscript.

ACKNOWLEDGMENT

The author's thank Drs Michael Bernstein, Sara Duncan and Eva Lenz for NMR spectroscopy support and Mrs Hemma Pancholi for detailed analysis work.

ABBREVIATIONS

CCR₄, CC chemokine receptor 4; CCL12, CC chemokine ligand 12; F (bioavailability), FLIPR (Fluorescence Imaging Plate Reader), FMAT (Fluorescent Microvolume Assay Technology), GPCR G protein-coupled receptor, MDC (macrophage-derived chemokine), PPB (plasma protein binding), TARC (T-cell and activation-related chemokine), UID (once-a-day), Vss (volume of distribution at steady state).


- (3) Proudfoot, A. E. I. Chemokine receptors: multifaceted therapeutic targets. *Nat. Rev. Immunol.* **2002**, 2 (2), 106–115.
- (4) Bonocchi, R.; Bianchi, G.; Bordinon, P. P.; D'Ambrosio, D.; Lang, R.; Borsatti, A.; Sozzani, S.; Allavena, P.; Gray, P. A.; Mantovani, A.; Sinigaglia, F. Differential Expression of Chemokine Receptors and Chemotactic Responsiveness of Type 1 T Helper Cells (Th1) and Th2s. *J. Exp. Med.* **1998**, 187

- (1), 129–134.
- (5) Bochner, B. S.; Hudson, S. A.; Xiao, H. Q.; Liu, M. C. Release of Both CCR4-Active and CXCR3-Active Chemokines during Human Allergic Pulmonary Late-Phase Reactions. *J. Allergy Clin. Immunol.* **2003**, *112* (5), 930–934.
- (6) Pilette, C.; Francis, J. N.; Till, S. J.; Durham, S. R. CCR4 Ligands Are up-Regulated in the Airways of Atopic Asthmatics after Segmental Allergen Challenge. *Eur. Respir. J.* **2004**, *23* (6), 876–884.
- (7) Hall, D.; Ford, A.; Hodgson, S. Therapeutic Potential of CCR4 Antagonists. In *New Drugs and Targets for Asthma and COPD*; Karger Medical and Scientific Publishers, 2010; Vol. 39, pp 161–165.
- (8) Newhouse, B.; Allen, S.; Fauber, B.; Anderson, A. S.; Eary, C. T.; Hansen, J. D.; Schiro, J.; Gaudino, J. J.; Laird, E.; Chantry, D.; Eberhardt, C.; Burgess, L. E. Racemic and Chiral Lactams as Potent, Selective and Functionally Active CCR4 Antagonists. *Bioorg. Med. Chem. Lett.* **2004**, *14* (22), 5537–5542.
- (9) Yokoyama, K.; Ishikawa, N.; Igarashi, S.; Kawano, N.; Masuda, N.; Hattori, K.; Miyazaki, T.; Ogino, S. ichi; Orita, M.; Matsumoto, Y.; Takeuchi, M.; Ohta, M. Potent CCR4 Antagonists: Synthesis, Evaluation, and Docking Study of 2,4-Diaminoquinazolines. *Bioorganic Med. Chem.* **2008**, *16* (17), 7968–7974.
- (10) Yokoyama, K.; Ishikawa, N.; Igarashi, S.; Kawano, N.; Hattori, K.; Miyazaki, T.; Ogino, S.; Matsumoto, Y.; Takeuchi, M.; Ohta, M. Discovery of Potent CCR4 Antagonists: Synthesis and Structure–activity Relationship Study of 2,4-Diaminoquinazolines. *Bioorg. Med. Chem.* **2008**, *16* (14), 7021–7032.
- (11) Burdi, D. F.; Chi, S.; Mattia, K.; Harrington, C.; Shi, Z.; Chen, S.; Jacutin-Porte, S.; Bennett, R.; Carson, K.; Yin, W.; Kansra, V.; Gonzalo, J.-A.; Coyle, A.; Jaffee, B.; Ocain, T.; Hodge, M.; LaRosa, G.; Harriman, G. Small Molecule Antagonists of the CC Chemokine Receptor 4 (CCR4). *Bioorg. Med. Chem. Lett.* **2007**, *17* (11), 3141–3145.
- (12) Purandare, A. V.; Wan, H.; Somerville, J. E.; Burke, C.; Vaccaro, W.; Yang, X.; McIntyre, K. W.; Poss, M. A. Core Exploration in Optimization of Chemokine Receptor CCR4 Antagonists. *Bioorganic Med. Chem. Lett.* **2007**, *17* (3), 679–682.
- (13) Allen, S.; Newhouse, B.; Anderson, A. S.; Fauber, B.; Allen, A.; Chantry, D.; Eberhardt, C.; Odingo, J.; Burgess, L. E. Discovery and SAR of Trisubstituted Thiazolidinones as CCR4 Antagonists. *Bioorganic Med. Chem. Lett.* **2004**, *14* (7), 1619–1624.
- (14) Liu, C.-J.; Yu, S.-L.; Liu, Y.-P.; Dai, X.-J.; Wu, Y.; Li, R.-J.; Tao, J.-C. Synthesis, Cytotoxic Activity Evaluation and HQSAR Study of Novel Isosteviol Derivatives as Potential Anticancer Agents. *Eur. J. Med. Chem.* **2016**, *115*, 26–40.
- (15) Procopiou, P. A.; Barrett, J. W.; Barton, N. P.; Begg, M.; Clapham, D.; Copley, R. C. B.; Ford, A. J.; Graves, R. H.; Hall, D. A.; Hancock, A. P.; Hill, A. P.; Hobbs, H.; Hodgson, S. T.; Jumeaux, C.; Lacroix, Y. M. L.; Miah, A. H.; Morris, K. M. L.; Needham, D.; Sheriff, E. B.; Slack, R. J.; Smith, C. E.; Sollis, S. L.; Staton, H. Synthesis and Structure–Activity Relationships of Indazole Arylsulfonamides as Allosteric CC-Chemokine Receptor 4 (CCR4) Antagonists. *J. Med. Chem.* **2013**, *56* (5), 1946–1960.
- (16) Pease, J. E.; Horuk, R. Chemokine Receptor Antagonists: Part 1. *Expert Opin. Ther. Pat.* **2009**, *19* (1), 39–58.
- (17) Cahn, A.; Hodgson, S.; Wilson, R.; Robertson, J.; Watson, J.; Beerahee, M.; Hughes, S. C.; Young, G.; Graves, R.; Hall, D.; van Marle, S.; Solari, R. Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2239633, a CC-Chemokine Receptor 4 Antagonist, in Healthy Male Subjects: Results from an Open-Label and from a Randomised Study. *BMC Pharmacol. Toxicol.* **2013**, *14* (1), 14.
- (18) Andrews, G.; Jones, C.; Wreggett, K. A. An Intracellular Allosteric Site for a Specific Class of Antagonists of the CC Chemokine G Protein-Coupled Receptors CCR4 and CCR5. *Mol. Pharmacol.* **2008**, *73* (3), 855–867.
- (19) Slack, R. J.; Russell, L. J.; Barton, N. P.; Nalesso, G.; Thompson, S.-A.; Allen, M.; Chen, Y. H.; Barnes, A.; Hodgson, S. T.; Hall, D. A. Antagonism of Human CC-Chemokine Receptor 4 Can Be Achieved through Three Distinct Binding Sites on the Receptor. *Pharmacol. Res. Perspect.* **2013**, *1* (2), e00019.
- (20) Baxter, A.; Timothy, J.; Kindon, N.; Roberts, B.; Steele, J.; Stocks, M.; Nicholas, T. Preparation of N-pyrazinylthiophenesulfonamides as Chemokine Receptor Modulators. WO 2003051870, 2003.
- (21) Davis, A. M.; Teague, S. J.; Kleywegt, G. J. Application and Limitations of X-Ray Crystallographic Data in Structure-Based Ligand and Drug Design. *Angew. Chem. Int. Ed. Engl.* **2003**, *42* (24), 2718–2736.
- (22) Luker, T.; Bonnert, R.; Paine, S. W.; Schmidt, J.; Sargent, C.; Cook, A. R.; Cook, A.; Gardiner, P.; Hill, S.; Weyman-Jones, C.; Patel, A.; Thom, S.; Thorne, P. Zwitterionic CRTh2 Antagonists. *J. Med. Chem.* **2011**, *54* (6), 1779–1788.
- (23) Grime, K. H.; Barton, P.; McGinnity, D. F. Application of In Silico, In Vitro and Preclinical Pharmacokinetic Data for the Effective and Efficient Prediction of Human Pharmacokinetics. *Mol. Pharm.* **2013**, *10* (4), 1191–1206.

For Table of Contents Use Only

The discovery of AZD-2098 and AZD-1678, two potent and bioavailable CCR₄ receptor antagonists.

Nicholas Kindon, Glen Andrews, Andrew Baxter, David Cheshire, Paul Hemsley, Timothy Johnson, Yu-Zhen Liu, Dermot McGinnity, Mark McHale, Antonio Mete, James Reu-berson, Bryan Roberts, John Steele, Barry Teobald, John Unitt, Deborah Vaughan, Iain Walters, and Michael J. Stocks






Table of Contents graphic

88x34mm (151 x 151 DPI)